Vor Biopharma Q4 2025 Earnings Results & Report

Vor Biopharma EPS Results

• Actual EPS: $307.61
• Consensus EPS: N/A
• Beat/Miss: N/A
• One Year Ago EPS: N/A
• EPS Beat Rate: 1 of last 8 quarters

Vor Biopharma Revenue Results

• Actual Revenue: N/A
• Expected Revenue: N/A
• Beat/Miss: N/A
• YoY Revenue Growth: N/A

Vor Biopharma (NASDAQ:VOR) is a clinical-stage biotechnology company focused on developing engineered hematopoietic stem cell and targeted immunotherapy treatments for cancer, particularly hematologic malignancies such as acute myeloid leukemia (AML). The company’s approach is designed to combine gene-edited blood stem cells with targeted therapies intended to improve the ability to treat disease while protecting healthy blood-forming cells.

Vor’s technology platform has included engineered hematopoietic stem cells designed to remove or alter specific cell-surface targets, along with targeted immunotherapies intended to eliminate malignant cells that retain those targets. Its development programs have included VOR33, an engineered stem cell therapy designed to lack the CD33 protein, and VCAR33, a CD33-directed CAR-T cell therapy. The company has evaluated these approaches as potential components of a treatment strategy for AML and other blood cancers.

Founded in 2015 and headquartered in Cambridge, Massachusetts, Vor Biopharma operates primarily as a research and clinical-development company serving the biopharmaceutical market. Its programs are in development and have not established products broadly available to patients. Vor Biopharma’s leadership has included Robert Ang, M.D., as chief executive officer.